TARS
Tarsus Pharmaceuticals Inc

911
Mkt Cap
$3.21B
Volume
544,461.00
52W High
$85.25
52W Low
$38.51
PE Ratio
-46.92
TARS Fundamentals
Price
$77.43
Prev Close
$75.52
Open
$73.61
50D MA
$72.34
Beta
0.72
Avg. Volume
541,035.80
EPS (Annual)
-$1.59
P/B
9.36
Rev/Employee
$1.22M
$3,086.48
Loading...
Loading...
News
all
press releases
Artisan Partners Limited Partnership Boosts Stock Position in Tarsus Pharmaceuticals, Inc. $TARS
Artisan Partners Limited Partnership lifted its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 3.5% in the third quarter, according to the company in its most recent...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Tarsus Pharmaceuticals (NASDAQ:TARS) Downgraded to Hold Rating by Wall Street Zen
Wall Street Zen lowered Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday...
MarketBeat·3d ago
News Placeholder
Tarsus Pharmaceuticals (NASDAQ:TARS) Downgraded to Hold Rating by Zacks Research
Zacks Research cut shares of Tarsus Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Wednesday...
MarketBeat·4d ago
News Placeholder
HC Wainwright Brokers Decrease Earnings Estimates for TARS
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Equities research analysts at HC Wainwright dropped their Q1 2026 earnings per share (EPS) estimates for shares of Tarsus Pharmaceuticals in...
MarketBeat·5d ago
News Placeholder
Tarsus Pharmaceuticals (NASDAQ:TARS) Given New $105.00 Price Target at Oppenheimer
Oppenheimer lifted their price target on shares of Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the company an "outperform" rating in a report on Wednesday...
MarketBeat·6d ago
News Placeholder
Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target Raised to $90.00 at Guggenheim
Guggenheim upped their target price on Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the company a "buy" rating in a report on Wednesday...
MarketBeat·6d ago
News Placeholder
Analysts Offer Predictions for TARS FY2030 Earnings
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Analysts at HC Wainwright issued their FY2030 EPS estimates for Tarsus Pharmaceuticals in a research report issued on Tuesday, February...
MarketBeat·6d ago
News Placeholder
Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Up - Time to Buy?
Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Up - Here's What Happened...
MarketBeat·7d ago
News Placeholder
Tarsus Pharmaceuticals Q4 Earnings Call Highlights
Tarsus Pharmaceuticals (NASDAQ:TARS) reported fourth-quarter and full-year 2025 results highlighting rapid growth for XDEMVY, the company's FDA-approved treatment for Demodex blepharitis (DB), and...
MarketBeat·7d ago
News Placeholder
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Beats Revenue Estimates
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of -5.26% and +4.63%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7d ago
<
1
2
...
>

Latest TARS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.